ReviewFundamental research2024
Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review.
Review in Fundamental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Impact of COVID-19 pandemic waves on colorectal cancer stage migration and diagnostic delays.Frontiers in oncology · 2026Article
- Global determinants of gynecologic cancer incidence and mortality: A cluster-based analysis with predictive insights.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Temporal Trends and Patient Stratification in Lung Cancer: A Comprehensive Clustering Analysis from Timis County, Romania.Cancers · 2025Article
- Comparison and trend analysis of cancer incidence in China and globally in 2022.World journal of clinical oncology · 2025Review
- Benefits and challenges of cervical cancer screening since the implementation of the 'two cancer' screening programme in China: findings from Shangyu, Zhejiang in 2019-23.Journal of global health · 2025Article
- The effect of the COVID-19 pandemic on clinical and pathologic stages of patients diagnosed with breast cancer.Irish journal of medical science · 2025Article
- Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.Therapeutic advances in medical oncology · 2025Article
- Human Papillomavirus Self-Sampling for Unscreened Women Aged 24 Years During the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2024Article
- Monitoring and prediction of pathogenic microorganisms in the atmosphere.Fundamental research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sudden onset of the coronavirus disease 2019 (COVID-19) in January 2020 has affected essential global health services. Cancer-screening services that can reduce cancer mortality are strongly affected. However, the specific role of COVID-19 in cancer screening is not fully understood. This study aimed to assess the efficiency of global cancer screening programs before and during the COVID-19 pandemic and to promote potential cancer-screening strategies for the next pandemic. Electronic searches in PubMed, Embase, and Web of Science, and manual searches were performed between January 1, 2020 and March 1, 2023. Cohort studies that reported the number of participants who underwent cancer screening before and during the COVID-19 pandemic were included. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale. Differences in cancer-screening rates were estimated using the incidence rate ratio (IRR). Fifty-five cohort studies were included in this meta-analysis. The screening rates of colorectal cancer using invasive screening methods (Pooled IRR = 0.52, 95% CI: 0.42 to 0.65,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.